Dr. Tara Bishop, Founder and Managing Director of Black Opal Ventures, gave the keynote at Weill Cornell's 6th Annual Primary Care & Hospital Medicine Innovations Symposium.
New York City - Dr. Tara Bishop gave the keynote at Weill Cornell Medicine's 6th Annual Primary Care & Hospital Medicine Innovations Symposium on May 25th . The symposium brings together Weill Cornell Medicine faculty, students, and affiliates to discuss advancing healthcare practices with several talks and the Competitive Seed Grant presentations. Dr. Bishop, an esteemed general internist and Associate Professor at Weill Cornell Medicine, shared her insights on the complex healthcare landscape outside the walls of academic medical centers. She highlighted several examples of successful innovations and startups, underscoring their ability to address various challenges faced by hospitals. The importance of clinician involvement in innovation resonated with the audience, who were excited by the opportunity to participate in this landscape through Clinical Advisory Boards. Dr. Bishop said, "I think it is critically important to have people who have on the ground clinical experience, who have regulatory experience, and who know the practicalities."
As the Managing Director of Black Opal Ventures, a venture capital firm specializing in healthcare technology, Dr. Bishop brings unique expertise and experience in the healthcare industry. Her work focuses on identifying and supporting promising startups and innovative solutions that have the potential to revolutionize the industry. Organizers of the 6th Annual Primary Care & Hospital Medicine Innovations Symposium expressed their gratitude to Dr. Bishop for her commitment to advancing the field of healthcare and for sharing her experience leaving Cornell's academic medical center.
The Primary Care & Hospital Medicine Innovations Symposium is an event bringing together affiliates of Weill Cornell Medicine to discuss innovation in the space. You can watch this year's event here. Black Opal Ventures aims to improve health outcomes for all by investing in companies at the collision of healthcare and technology.